The failure to report the issue has not put patients at risk, the F.D.A. said, but the drugmaker could face criminal and civil penalties.
Published: August 6, 2019 at 02:00AM
from NYT Health https://ift.tt/2M3PJn4
The failure to report the issue has not put patients at risk, the F.D.A. said, but the drugmaker could face criminal and civil penalties.
Published: August 6, 2019 at 02:00AM
from NYT Health https://ift.tt/2M3PJn4